Research Papers:

This article has been corrected. Correction in: Oncotarget. 2019; 10:6396-6396.

MiR-451 as a new tumor marker for gastric cancer

Yong Shen _, Jiao-Mei Gong, Li-Li Zhou and Jia-He Sheng

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:56542-56545. https://doi.org/10.18632/oncotarget.17239

Metrics: PDF 2087 views  |   HTML 2278 views  |   ?  


Yong Shen1,2, Jiao-Mei Gong3, Li-Li Zhou4 and Jia-He Sheng1

1Department of Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China

2Department of Pathology and Pathophysiology, Medical School of Southeast University, Nanjing, Jiangsu, China

3Department of Clinical Laboratory, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

4Department of Hepatobiliary Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China

Correspondence to:

Yong Shen, email: [email protected]

Keywords: MiR-451, gastric cancer, diagnoses, pathology

Received: March 03, 2017    Accepted: March 23, 2017    Published: April 19, 2017


Gastric cancer is the second most common malignancy in China. However, the prognosis for gastric cancer patients remains poor. The purpose of this study was to investigate whether miR-451 was a potential prognostic biomarker for gastric cancer. Fresh tissues were immediately frozen in liquid nitrogen until use. The plasma was extracted and quantitative real-time polymerase chain reaction was performed to detect miR-451 expression. The Student’s t test analysis and multivariate Cox regression analysis were performed to analyze expression of miR-451. The analysis results showed that the expression level of miR-451 was decreased expression in gastric cancer tissue. The down-regulation of miR-451 tended to be positively correlated with tumor stage, lymphatic metastasis and shorter overall survival of patients. MiR-451 may be a potential biomarker and a potential therapeutic target for the diagnoses and prognosis of gastric cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17239